Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. Issue 6 (18th August 2017)

• Record Type: Journal Article
• Authors: Vicari, Alain P.; Schoepfer, Alain M.; Meresse, Bertrand; Goffin, Laurence; Léger, Olivier; Josserand, Soheila; Guégan, Nicolas; Yousefi, Shida; Straumann, Alex; Cerf-Bensussan, Nadine; Simon, Hans-Uwe; Chvatchko, Yolande
• Is Part Of: MAbs. Volume 9:Issue 6(2017)
• Page Start: 927
• Page End: 944
• Publication Date: 2017-08-18
• Subjects: Antibody -- celiac disease -- cis -- eosinophilic esophagitis -- humanized -- interleukin-15 -- IL-15 -- trans; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1332553
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Interleukin-15 (IL-15) is a critical regulator of immune responses, especially at mucosal interfaces within the gastro-intestinal tract. Here, we describe the discovery and characterization of a humanized antibody to IL-15. Data from its epitope and mode of action, cell biology and primate pharmacology, as well as translational studies in human samples and in vivo proof-of-concept experiments in mouse models demonstrate the therapeutic potential of this new antibody targeting IL-15 for refractory celiac disease and eosinophilic esophagitis.